MedTrace Logo

Noninvasive Diagnostic Platform for Liver Fibrosis and Portal Hypertension

NCT03277651 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2018-01-10

No results posted yet for this study

Summary

This study is to establish a noninvasive diagnostic platform based on hemodynamic information for the assessment of liver fibrosis, liver cirrhosis and portal hypertension.

Conditions

  • Liver Fibrosis
  • Cirrhosis
  • Portal Hypertension

Interventions

DIAGNOSTIC_TEST

hemodynamics tests

Hemodynamics tests for intrahepatic blood flow by colour doppler ultrasound

Sponsors & Collaborators

  • Shanghai Zhongshan Hospital

    lead OTHER

Principal Investigators

  • Wei Jiang · Fudan University

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-09
Primary Completion
2019-12-31
Completion
2020-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03277651 on ClinicalTrials.gov